STOCK TITAN

Callan JMB closes roughly $1.5M private placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Callan JMB Inc. (CJMB) closed a private placement on November 10, 2026, selling 1,363,639 common shares at $1.10 each for approximately $1.5 million in gross proceeds, before placement-agent fees and other offering expenses. The Securities Purchase Agreement permits sales of up to $3,000,000 of shares. Chairman, President and CEO Wayne Williams purchased 363,637 shares for $400,000.70; persons affiliated with him and other company insiders purchased an aggregate of 1,000,002 shares.

The company intends to use net proceeds for strategic growth initiatives and other corporate purposes. Alexander Capital, L.P. served as exclusive placement agent on a reasonable best efforts basis. Callan JMB paid a cash fee equal to 6.0% of gross proceeds, reimbursed certain expenses up to $35,000, and issued warrants to purchase up to 54,546 shares at $1.10 per share. The warrants are immediately exercisable and expire five years from the commencement of sales. The shares are unregistered securities and bear a restrictive legend.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Shares sold 1,363,639 shares Private placement closed November 10, 2026
Purchase price $1.10 per share Private placement
Gross proceeds Approximately $1.5 million Before placement-agent fees and other offering expenses
Purchase Agreement sale limit Up to $3,000,000 Aggregate permitted share sales
Wayne Williams purchase 363,637 shares; $400,000.70 Wayne Williams is the Chairman, President and CEO
Placement agent fee and expenses 6.0% of gross proceeds; expenses up to $35,000 Compensation under the Placement Agency Agreement
Placement agent warrants Up to 54,546 shares at $1.10 per share Immediately exercisable; expire five years from commencement of sales
private placement financial
"in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
restrictive legend regulatory
"will bear a restrictive legend"
A restrictive legend is a notation printed on a stock certificate or encoded on an electronic security record that warns the holder the shares are subject to legal or contractual transfer limits. It identifies why the shares cannot be freely sold or transferred — for example because they are unregistered under federal securities laws, issued under a private placement, subject to lock-up agreements, or governed by contractual resale restrictions — and transfer usually requires satisfying conditions (such as registration, a compliance certificate, or a legal opinion) or formal removal of the legend by the issuer or transfer agent before the shares can be moved into a freely transferable form.
Section 4(a)(2) regulatory
"exemption from registration provided by Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506(b) regulatory
"Rule 506(b) of Regulation D"
Rule 506(b) is a U.S. securities exemption that lets companies sell shares or debt privately without full public registration, provided sales are primarily to accredited investors, up to 35 non‑accredited but financially knowledgeable buyers, and there is no public advertising or solicitation. It matters to investors because offerings under 506(b) usually include less public disclosure than registered securities—like buying from a private seller rather than a retail store—so buyers must do more of their own fact‑checking and rely on their financial sophistication.
accredited investor regulatory
"each Purchaser is an “accredited investor”"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
Rule 144 regulatory
"conditions prescribed by SEC Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CJMB shares were sold in the private placement, and at what price?

Callan JMB sold 1,363,639 shares at $1.10 per share for approximately $1.5 million in gross proceeds, before placement-agent fees and other offering expenses.

How many CJMB shares did Wayne Williams and other insiders purchase?

Chairman, President and CEO Wayne Williams purchased 363,637 shares for $400,000.70. Persons affiliated with him and other company insiders purchased an aggregate of 1,000,002 shares.

What are the terms of the CJMB placement agent warrants?

The placement agent or its designees received warrants to purchase up to 54,546 shares at $1.10 per share. They are immediately exercisable and expire five years from the commencement of sales in the private placement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002032545 0002032545 2026-11-10 2026-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 10, 2026

 

Callan JMB Inc.
(Exact name of registrant as specified in its charter)

 

Nevada   001-42506   99-0931141

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

244 Flightline Drive

Spring Branch, Texas

  78070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (830) 438-0395

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   CJMB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On November 10, 2026, Callan JMB Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement (the “Private Placement”), an aggregate of 1,363,639 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.10 per share, for aggregate gross proceeds of approximately $1.5 million, before deducting placement agent fees and other offering expenses. The Purchase Agreement permits the sale of up to an aggregate of $3,000,000 of Shares.

 

The Purchasers include Wayne Williams, the Company’s Chairman, President and Chief Executive Officer, who purchased 363,637 Shares for an aggregate purchase price of $400,000.70, and persons affiliated with Mr. Williams and other insiders of the Company, who purchased an aggregate of 1,000,002 Shares. The Private Placement was approved by the Company’s Board of Directors, with Mr. Williams having disclosed his interest in the transaction.

 

The closing of the Private Placement occurred on November 10, 2026. The Company intends to use the net proceeds derived from the Private Placement for strategic growth initiatives and for other corporate purposes.

 

The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers, and provides for indemnification of the Purchasers by the Company. The Shares are unregistered securities and will bear a restrictive legend.

 

The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement and as of specific dates, were solely for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties.

 

Alexander Capital, L.P. (the “Placement Agent”) acted as exclusive placement agent for the Private Placement on a reasonable best efforts basis pursuant to a Placement Agency Agreement, dated November 10, 2026, between the Company and the Placement Agent (the “Placement Agency Agreement”). Pursuant to the Placement Agency Agreement, the Company paid the Placement Agent a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement, reimbursed the Placement Agent for certain expenses up to $35,000, and issued to the Placement Agent, or its designees, warrants (the “Placement Agent Warrants”) to purchase up to 54,546 shares of Common Stock (the “Warrant Shares”), representing 4.0% of the Shares sold in the Private Placement, at an exercise price of $1.10 per share. The Placement Agent Warrants are exercisable immediately and expires five years from the commencement of sales in the Private Placement. The Placement Agency Agreement contains customary representations, warranties, indemnification and contribution obligations.

 

The foregoing descriptions of the Purchase Agreement, the Placement Agency Agreement and the Placement Agent Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the Purchase Agreement, the Placement Agency Agreement and the form of Placement Agent Warrant, copies of which are filed as Exhibits 10.1, 10.2 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

 

This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares contain a legend stating the same.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The Shares and the Placement Agent Warrant (and the Warrant Shares) are being offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, based in part on representations that each Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D and is acquiring the securities for investment purposes. No general solicitation was used in connection with the offer or sale of such securities. Such securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

 
 

 

Item 8.01 Other Events.

 

On November 12, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Forward-Looking Statements

 

This Report and the exhibit(s) attached hereto, including the disclosures set forth herein, contain certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “intends,” “anticipates,” “expects,” “estimates,” “believes” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

 

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein. The Company’s actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements. The Company expressly disclaims any obligation or intention to update these forward-looking statements contained in this Report.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
4.1   Form of Placement Agent Warrant
10.1   Securities Purchase Agreement, dated as of November 10, 2026, by and between Callan JMB Inc. and the purchasers named therein*
10.2   Placement Agency Agreement, dated November 10, 2026, by and between Callan JMB Inc. and Alexander Capital, L.P.
99.1   Press Release dated November 12, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Certain personal information of the Purchasers has been omitted pursuant to Item 601(a)(6) of Regulation S-K.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 13, 2026 Callan JMB Inc.
     
  By: /s/ Wayne Williams
  Name: Wayne Williams
  Title: Chief Executive Officer

 

 

 

 

 

 

Exhibit 99.1

 

Callan JMB CEO and Management Team Invest $1.5 Million in Common-Only Transaction at a Premium of $1.10 Per Share, Reinforcing Confidence in Growth Strategy

 

SPRING BRANCH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a provider of logistics, emergency preparedness, and critical supply chain solutions for the healthcare industry and government organizations, today announced that CEO Wayne Williams and members of its executive leadership team have invested $1.5 million personally through the purchase of common stock at a premium of $1.10 per share.

 

The investment underscores management’s conviction in Callan JMB’s strategic direction, operational progress, and short- and long-term growth opportunities.

 

“Our leadership team is putting its own capital to work because we believe in the path ahead,” said Wayne Williams, Chief Executive Officer of Callan JMB. “This is a direct expression of our confidence in the Company’s strategy, and our commitment to building value alongside shareholders.”

 

The investment arrives as Callan JMB has recently completed multiple important initiatives across healthcare preparedness, expanded pharmaceutical supply chain infrastructure, increased advanced manufacturing, and launched strategic partnerships with U.S. government-focused programs, achieving the goal of strengthening domestic healthcare resiliency and critical medical supply chains. Management believes the Company’s rapidly growing pipeline of business opportunities positions it to capitalize on rising demand while executing its plan for growth and operational excellence.

 

“We believe the strongest signal we can send is to invest our own capital at a price that is at a multiple above the current market, but still at what we perceive to be a discount to the true value of our shares. Investing alongside our shareholders demonstrates our confidence in the company,” said Christopher Shields, Interim Chief Financial Officer. “We remain focused on disciplined execution and creating sustainable value for all stakeholders.”

 

Proceeds from the investment are expected to support strategic growth initiatives and other corporate objectives that significantly strengthen the Company’s market position.

 

Shareholder Alignment

 

By committing personal capital at this level, Callan JMB’s executive leadership is further aligning its interests with those of shareholders. The investment reinforces management’s total confidence in the Company’s strategic initiatives and its commitment to responsible stewardship of shareholder capital.

 

The shares purchased do not benefit from any registration rights and may only be sold or transferred in accordance with the holding periods and other conditions prescribed by SEC Rule 144.

 

 

 

 

About Callan JMB Inc.

 

Callan JMB Inc. (NASDAQ: CJMB) provides logistics, infrastructure, and operational services supporting the healthcare industry, emergency management agencies, government organizations, and other entities responsible for maintaining essential services. The Company’s capabilities include product fulfillment, specialty packaging, warehousing, cold-chain logistics, monitoring, regulatory compliance, emergency preparedness, and response operations. Through continued expansion, Callan JMB is leveraging its expertise in critical infrastructure and supply chain management to address challenges of national importance.

 

Investor Contact

Valter Pinto

Managing Director

KCSA Strategic Communications

CallanJMB@kcsa.com

(212) 896-1254

 

Media Contact

Arian Hopkins

ahopkins@callanjmb.com

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws. Such statements include, but are not limited to, statements regarding the Company’s growth strategy, business opportunities, operational expansion, healthcare preparedness initiatives, manufacturing capabilities, supply chain objectives, expected market demand, strategic partnerships, workforce development initiatives, and other statements that are not historical facts. These forward-looking statements are based on current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Investors are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for a discussion of factors that could affect future results. The Company undertakes no obligation to update any forward-looking statements except as required by law.

 

 

 

 

Filing Exhibits & Attachments

8 documents

Keep reading